Spots Global Cancer Trial Database for pelareorep
Every month we try and update this database with for pelareorep cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | NCT05514990 | Recurrent Plasm... Refractory Plas... | Bortezomib Dexamethasone Pelareorep Pembrolizumab | 18 Years - | University of Southern California | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | NCT04445844 | Anatomic Stage ... Locally Advance... Metastatic Trip... Prognostic Stag... Triple-negative... | Pelareorep Quality-of-Life... Questionnaire A... Retifanlimab | 18 Years - | Rutgers, The State University of New Jersey | |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | NCT04445844 | Anatomic Stage ... Locally Advance... Metastatic Trip... Prognostic Stag... Triple-negative... | Pelareorep Quality-of-Life... Questionnaire A... Retifanlimab | 18 Years - | Rutgers, The State University of New Jersey | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
| Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT02101944 | Anemia Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Laboratory Biom... Pelareorep | 18 Years - | National Cancer Institute (NCI) | |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT02101944 | Anemia Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Laboratory Biom... Pelareorep | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
